Amedica(R) Signs Joint Venture Agreement With Orthopaedic Synergy(R)

SALT LAKE CITY, February 24, 2010 - Amedica Corporation (AC), a spinal and orthopaedic implant and instrument
company focused on unique silicon nitride (SiN) ceramic technologies,
announced today an agreement with Orthopaedic Synergy, Inc. (OSI), a holding
company for OMNIlife Science(TM) and Enztec, both global designers,
manufacturers and distributors of leading edge reconstructive surgery
implants and instrumentation.

Amedica is a full-line spinal implant company that owns and markets
silicon nitride ceramic technologies that are now being utilized in spinal
implant applications; however, the unique SiN materials have disruptive
characteristics for hip and knee implant applications, as well. The material
is fracture resistant; its bearing/articulating surfaces do not produce wear
debris that is linked to osteolysis-related, re-operations. Additionally, the
implants are BioActive(TM) with a hydrophilic surface and a conductive
cancellous structure to enhance bone in-growth and attachment.

The Joint Venture Development Agreement will allow the development,
regulatory approval and distribution of SiN articulating hip and knee
implants in the U.S. and abroad. This agreement further secures both
companies' competitive positions in the largest segment of orthopaedic care.

Orthopaedic Synergy is a global reconstructive hip and knee implant and
instrument concern that designs, manufactures and distributes its products.
Its corporate headquarters is located in East Taunton, Mass., and its design,
development and manufacturing center is based in Christchurch, New Zealand.
OSI is known for leading-edge innovation, cost-effective, outcome-focused
implant systems and deep orthopaedic executive management experience.

"Amedica's SiN technology is ideally suited for the innovative modular
hip and knee replacement products developed and marketed by our company, and
we view this Joint Venture Development Agreement as a significant step
forward in solving the issue of wear in reconstructive orthopaedic products,"
says Nik Nikolaev, Chairman and Chief Executive Officer of Orthopaedic
Synergy, Inc.

"Finding the appropriate material to use as a bearing surface in Total
Joint Arthroplasty has been an elusive goal, especially for Total Hip
Replacement. We have been investigating alternate materials for some time,
and we are convinced that Amedica's SiN technology is the answer. We are
proud that they chose OSI to be their partner," says George Cipolletti,
President of OMNIlife Science.

"We are pleased that this agreement is now in place. SiN is a disruptive
human implant material that has application in spine, reconstructive surgery
and other orthopaedic implant indications. We are honored to be in this
relationship with Orthopaedic Synergy - it is truly an alliance that, in
time, can clearly enhance patient outcomes," says Ben Shappley, Chief
Executive Officer, President and Director of Amedica.

About Orthopaedic Synergy:

Orthopaedic Synergy, Inc. is a global reconstructive orthopaedic concern
that functions as a holding company for OMNIlife Science, Inc. and Enztec,
Ltd. The Company designs, develops and distributes FDA cleared and CE
approved reconstructive orthopaedic implants that represent leading edge
technologies.

About Amedica:

Amedica Corporation is ISO 13485 certified and its products are FDA
cleared and CE approved. Amedica Corporation is an emerging orthopaedic
implant company focused on using its silicon nitride ceramic technologies to
develop and commercialize a broad range of innovative, unique spine and total
joint implants for the growing orthopaedic device market. It has brought to
market various spinal implant products, while products under development
include reconstructive hip and knee implants that represent a new standard of
care in total joint implants based on superior performance, safety and
efficacy.

Cheryl Seredy, Falls Communications, +1-216-472-2385, cseredy at fallscommunications.com; or Steve Zeiger, Amedica Corporation, +1-801-839-3500, szeiger at amedicacorp.com